Occam is pleased to announce the successful recruitment of Terry-Ann Burrell as CFO of Beam Therapeutics, a next generation gene editing platform company founded by three of the world’s leading CRISPR experts. To date, the company has raised over $225M in two rounds of financing led by ARCH and F-Prime.
For the last ten years, Terry Ann, as a leading investment banker, has worked with all types of companies from preclinical platforms to more established organizations with late stage clinical assets. She recently helped take Orchard Therapeutics and Editas public.
We believe that Terry-Ann’s intellectual curiosity, strong managerial capabilities, and robust financial strategic wisdom will serve Beam well as they leverage their game changing base-pair editing capabilities to advance multiple programs into the clinic.